Inhibrx Biosciences, Inc.

INBX

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Oct 30, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
INBRX-106	Phase 3	Head and Neck Squamous Cell Carcinoma (HNSCC)	-
INBRX-109	Phase 2	Conventional Chondrosarcoma	-
INBRX-106 - Hexavalent OX40 agonist antibody	Phase 2	Solid Tumor	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Oct 30, 2026INBRX-106 - Hexavalent OX40 agonist antibody

Primary completion for INBRX-106 - Hexavalent OX40 agonist antibody trial (NCT04198766) in Solid Tumor

Regulatory Approvals

INBX News